Compare HCA Health Inc (HCA) vs Innovative Industrial Properties Inc (IIPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Innovative Industrial Properties Inc — how do they compare? HCA Health Inc trades at $451.09 (market cap $96.35B), while Innovative Industrial Properties Inc trades at $51.83 (market cap $1.43B). The key difference: HCA Health Inc is far larger — about 67.4× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays the higher dividend (14.64%). Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Innovative Industrial Properties Inc for 86 Days on average.
| HCA | IIPR | |
|---|---|---|
Market Cap | $96.35B | $1.43B |
Volume | 1,079,453 | 394,222 |
Sector | Health | Real Estate |
52-Week High | $545.13 | $64.67 |
52-Week Low | $361.32 | $44.58 |
Typical Hold Time | 76 Days | 86 Days |
Enterprise Value | $146.88B | $1.96B |
Dividend Yield | 0.7% | 14.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $445.01, up 1.33% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $75.60 billion in 2025, with a net income margin of 8.77%. The stock is supported by a consensus analyst price target of $461.12 and a 63% buy rating. Recent news includes an upcoming Q3 2026 earnings call and completion of the College of Health Care Professions acquisition, highlighting growth initiatives amid ongoing legal investigations.
Outlook remains positive given solid demand and cost controls, but risks include payer-mix pressure and regulatory scrutiny. The stock offers value with a P/E of 14.92 and upside to the price target, though high debt levels and legal overhangs warrant caution for investors seeking stable healthcare exposure.
IIPR trades at $51.92, up 1.35% with bearish technical signals but attractive valuation metrics including P/E of 11.75 and P/B of 0.83. The REIT reported mixed Q2 2026 earnings, beating expectations with $1.36 EPS versus $1.02 expected, while revenue declined to $266M in 2025. Recent news highlights a $245M mezzanine loan commitment and a $1.90 quarterly dividend, though cash flow turned negative in 2025.
The stock presents a high-yield opportunity with 13%+ dividend yield but faces tenant default risks and sector volatility. Analyst consensus is mixed with 36% buy ratings and $84.67 price target suggesting 63% upside, though technical indicators remain bearish. Regulatory catalysts and balance sheet strength provide potential upside amid cannabis REIT sector challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →
